WASHINGTON — Congress has rebuffed drug companies’ appeals to reduce how much they have to pay for some seniors’ prescription costs — a rare defeat for the industry after a frenzied lobbying campaign.

Drug makers had pressed Republicans to use a sprawling appropriations deal to roll back a policy that makes them responsible for 70 percent of the prescription costs for seniors who reach the so-called “donut hole” in 2019. The “donut hole” is a gap in Medicare drug coverage in which beneficiaries are on the hook for sky-high prescription costs, up to a certain dollar amount.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • What a novel idea, increasing the rebates so that seniors won’t go broke before they break out of the donut hole. This is no surprise. Some makers of five and six figure drugs have already warned in their Forward Guidances that rebates will be increasing in 2018, with losses falling to their bottom line as they shed crocodile tears.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.